Naturalendo Tech Valuation

Is A168330 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Future Cash Flow Value
Significantly Below Future Cash Flow Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A168330 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate A168330's future cash flow value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate A168330's future cash flow value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A168330?

Key metric: As A168330 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A168330. This is calculated by dividing A168330's market cap by their current revenue.
What is A168330's PS Ratio?
PS Ratio	2.5x
Sales	₩21.69b
Market Cap	₩55.25b

A168330 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.8x
Enterprise Value/EBITDA	-34.2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A168330's PS Ratio compare to its peers?

The above table shows the PS ratio for A168330 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	2.1x
A420570 J2KBIO	1.5x	n/a	₩55.3b
A153710 Optipharm.CO.LTD	3x	n/a	₩67.7b
A251120 BIO-FD&CLtd	3.4x	n/a	₩64.7b
A084650 LabGenomics	0.5x	n/a	₩40.6b
A168330 Naturalendo Tech	2.5x	n/a	₩55.3b

Price-To-Sales vs Peers: A168330 is expensive based on its Price-To-Sales Ratio (2.5x) compared to the peer average (2.1x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does A168330's PS Ratio compare vs other companies in the KR Biotechs Industry?

41 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	7.9x	19.5%
A168330 Naturalendo Tech	2.5x	n/a	US$38.35m
A302440 SK bioscienceLtd	4x	9.18%	US$1.84b
A006280 GC Biopharma	0.6x	4.13%	US$918.01m

41 Companies		Estimated Growth	Market Cap
Industry Avg.	7.9x	21.2%
A168330 Naturalendo Tech	2.5x	n/a	US$38.35m

No more companies

Price-To-Sales vs Industry: A168330 is good value based on its Price-To-Sales Ratio (2.5x) compared to the KR Biotechs industry average (7.9x).

Price to Sales Ratio vs Fair Ratio

What is A168330's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A168330 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	2.5x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A168330's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/31 22:54
End of Day Share Price	2026/07/31 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Naturalendo Tech Co., Ltd. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Hyuk Jin Yoon	Eugene Investment & Securities Co Ltd.
Dong Ha Kim	Kyobo Securities Co., Ltd
Gi Kim	LS Securities Co., Ltd.